Leith Jonathan G, Clark David A, Matthews Thomas J, Rosenthal Kenneth L, Luscher Mark A, Barber Brian H, MacDonald Kelly S
Department of Immunology, University of Toronto, Toronto, Canada.
AIDS Res Hum Retroviruses. 2003 Nov;19(11):957-65. doi: 10.1089/088922203322588305.
Xenovaccination of rhesus macaques with human HLA Class I and II proteins has been demonstrated to elicit protective immunity against challenge with SIV grown in human cells. To determine if alloimmunization in humans could lead to protective immunity against HIV-1, we prospectively followed a small group of women receiving whole-cell alloimmunization in the form of leukocyte immunotherapy for recurrent spontaneous abortion. Whole-cell vaccine recipients and their respective partners (referred to as donors) provided pre- and postimmune blood samples for analysis. Study participants were HLA typed by sequence-specific PCR and antibodies specific for HLA Class I and II antigens were measured in recipient plasma. To determine if anti-HLA antibody responses detected in recipient plasma samples were capable of neutralizing HIV-1 in vitro, we grew laboratory strain HIV-1(IIIB) and primary isolate HIV-1(301660) in donor-derived CD4(+) T lymphocytes. The ability of purified whole IgG from responding patients to neutralizing infectivity of the respective donor-derived virus was then assayed in vitro. All donor-recipient pairs were determined to be HLA discordant for at least one Class I and one Class II locus. Two of seven female recipients in total made strong anti-HLA antibody responses specific to the HLA haplotype of the male donor in response to the alloimmunization regimen. For one recipient, IgG antibodies specific for donor HLA Class I and II antigens were able to neutralize both HIV-1(IIIB) and a primary isolate HIV-1(301660). In addition polyclonal anti-HLA class II antibodies against a single determinant (DR4) of this donor were also neutralizing. In contrast, the other recipient exhibiting antibodies only against donor HLA Class I antigens did not neutralize HIV-1(IIIB). Using samples from a small number of women undergoing leukocyte immunotherapy, we have demonstrated for the first time that allele-specific anti-HLA antibodies elicited through human alloimmunization are capable of neutralizing HIV-1 in vitro.
用人类HLA I类和II类蛋白对恒河猴进行异种接种已被证明能引发针对在人类细胞中生长的SIV攻击的保护性免疫。为了确定人类的同种免疫是否能导致针对HIV-1的保护性免疫,我们前瞻性地跟踪了一小群接受白细胞免疫疗法全细胞同种免疫以治疗复发性自然流产的女性。全细胞疫苗接种者及其各自的伴侣(称为供体)提供免疫前和免疫后的血液样本用于分析。通过序列特异性PCR对研究参与者进行HLA分型,并在接种者血浆中测量针对HLA I类和II类抗原的特异性抗体。为了确定在接种者血浆样本中检测到的抗HLA抗体反应是否能够在体外中和HIV-1,我们在供体来源的CD4(+) T淋巴细胞中培养实验室菌株HIV-1(IIIB)和原代分离株HIV-1(301660)。然后在体外测定来自有反应患者的纯化全IgG中和各自供体来源病毒感染性的能力。所有供体-接种者对至少在一个I类和一个II类基因座上被确定为HLA不一致。总共七名女性接种者中有两名在接受同种免疫方案后,针对男性供体的HLA单倍型产生了强烈的抗HLA抗体反应。对于一名接种者,针对供体HLA I类和II类抗原的IgG抗体能够中和HIV-1(IIIB)和原代分离株HIV-1(301660)。此外,针对该供体单个决定簇(DR4)的多克隆抗HLA II类抗体也具有中和作用。相比之下,另一名仅表现出针对供体HLA I类抗原抗体的接种者不能中和HIV-1(IIIB)。通过使用少量接受白细胞免疫疗法的女性的样本,我们首次证明通过人类同种免疫引发的等位基因特异性抗HLA抗体能够在体外中和HIV-1。